
Hereditary Angioedema Market
Description
Hereditary Angioedema Market Report and Forecast 2024-2032
The hereditary angioedema market was valued at USD 3.5 billion in 2023, driven by rising hereditary angioedema prevalence, advancements in genetic research, increased awareness and early diagnosis, a focus on prophylactic treatments, and regulatory support for rare disease therapies. It is expected to grow at a CAGR of 7.4% during the period 2024-2032 and likely to reach a market value of USD 6.7 billion by 2032.
Hereditary Angioedema Market Analysis
Hereditary angioedema is a rare genetic disorder characterised by sudden, recurrent episodes of severe swelling in various parts of the body, including the hands, feet, face, and airways. This condition is often triggered by stress or minor injuries and is caused by a deficiency or dysfunction in the C1 esterase inhibitor, leading to uncontrolled inflammation. Hereditary angioedema can be life-threatening when it affects the airways, making prompt diagnosis and treatment essential. Hereditary angioedema management focuses on preventing and controlling attacks through specialised therapies, such as C1 esterase inhibitors, bradykinin receptor antagonists, and kallikrein inhibitors, which provide relief and improve patients' quality of life.
Market Drivers
Rising Prevalence of Hereditary Angioedema: The increasing diagnosis of Hereditary angioedema is driving demand for targeted therapies. As awareness of hereditary angioedema grows among healthcare professionals and patients, more individuals are diagnosed, necessitating effective treatments to manage symptoms and prevent life-threatening complications.
Advancements in Genetic Research: Genetic research is improving understanding of hereditary angioedema, enabling the development of therapies that target the condition’s underlying causes. These advancements are driving pharmaceutical innovation, leading to the introduction of more specific and effective hereditary angioedema treatments, which is expanding the market.
Increased Awareness and Early Diagnosis: Awareness campaigns and improved diagnostic techniques are contributing to earlier hereditary angioedema diagnoses. Timely diagnosis allows for faster intervention, improving patient outcomes and increasing demand for therapies that help manage and prevent attacks, thus driving market growth.
Focus on Prophylactic Treatments: There is a growing focus on preventive treatments for hereditary angioedema, with patients and healthcare providers prioritising options that reduce attack frequency. This shift towards prophylactic therapies is driving demand for drugs that offer long-term management, such as C1 esterase inhibitors and kallikrein inhibitors.
Regulatory Support for Rare Disease Treatments: Regulatory bodies are increasingly supporting rare disease treatments by fast-tracking approvals and providing incentives for orphan drug development. This support encourages pharmaceutical companies to invest in hereditary angioedema treatment research and development, helping to expand the market and bring new therapies to patients more quickly.
Challenges
Limited Awareness in Developing Regions: In some developing countries, awareness of hereditary angioedema is low, resulting in underdiagnosis and insufficient treatment options. Limited healthcare infrastructure and a lack of knowledge among healthcare providers can hinder timely diagnosis, challenging efforts to expand access to hereditary angioedema treatments globally.
Adverse Effects of Current Therapies: Some hereditary angioedema treatments are associated with side effects, such as pain at the injection site, increased risk of infection, and allergic reactions. These adverse effects can reduce patient adherence, making it challenging for healthcare providers to balance treatment efficacy with patient comfort and safety.
Complex Treatment Regimens: Many hereditary angioedema therapies require regular administration via injection or infusion, which can be cumbersome for patients. This complexity can discourage adherence to long-term treatments, creating a challenge in ensuring consistent symptom control and attack prevention.
Challenges in Accurate Diagnosis: Accurate hereditary angioedema diagnosis can be challenging due to its rarity and symptom similarity to other conditions, such as allergies. Misdiagnosis can lead to inappropriate treatment, further complicating patient care and delaying access to effective hereditary angioedema therapies.
Future Opportunities
Expansion of Prophylactic Treatment Options: The market for prophylactic hereditary angioedema treatments is expanding as patients seek long-term management solutions. Pharmaceutical companies investing in developing and improving preventive therapies can capture a growing market segment focused on reducing attack frequency and improving quality of life.
Growing Demand for Personalised Medicine: Advances in genetic research offer opportunities to develop personalised hereditary angioedema treatments tailored to individual patient profiles. Personalised therapies that address specific genetic markers and treatment responses can enhance efficacy, providing patients with more targeted and effective care.
Emerging Markets with Improved Healthcare Access: Emerging markets, particularly in Asia and Latin America, present significant growth opportunities as healthcare access and infrastructure improve. Pharmaceutical companies can expand their reach by offering affordable and accessible hereditary angioedema treatments in these regions, broadening market potential.
Development of Oral Treatment Options: The development of oral hereditary angioedema treatments is an opportunity to provide more convenient options for patients. Oral medications eliminate the need for injections or infusions, improving patient adherence and potentially capturing a segment of the market seeking simplified treatment regimens.
Collaborations with Research Institutions: Collaborating with academic and research institutions can accelerate hereditary angioedema treatment development. Partnerships in research and clinical trials facilitate knowledge sharing and resource pooling, helping pharmaceutical companies bring new therapies to market more efficiently.
Hereditary Angioedema Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the market's future direction. These trends are expected to influence the landscape significantly, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
Hereditary Angioedema Market Segmentation
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
Hereditary Angioedema Market Competitive Landscape
Key players in the hereditary angioedema market include Takeda Pharmaceutical Company, CSL Behring, Pharvaris N.V., BioCryst Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Sanofi S.A., BioMarin Pharmaceutical Inc., Adverum Biotechnologies Inc., and Novartis AG. These companies focus on developing innovative hereditary angioedema treatments, investing in genetic research, and advancing biological therapies to provide effective management options. They are also pursuing strategic collaborations and clinical trials to enhance their offerings, aiming to address unmet patient needs and expand their presence in the rare disease treatment market.
Key Questions Answered in the Report
What are the primary drivers of growth in the hereditary angioedema market?
How are advancements in genetic research influencing new treatments for hereditary angioedema?
What challenges do patients and healthcare providers face with current hereditary angioedema therapies?
Which regions are expected to see the highest demand for hereditary angioedema treatments?
How is regulatory support affecting the development of rare disease therapies?
What role do prophylactic treatments play in managing hereditary angioedema?
How are digital health tools integrated into hereditary angioedema management for better patient outcomes?
What trends are emerging in the development of biologic therapies for hereditary angioedema?
Which drug classes are the most commonly used for hereditary angioedema, and why?
What strategies are leading companies using to expand their presence in emerging markets?
How is the demand for subcutaneous administration impacting the hereditary angioedema treatment landscape?
How do collaborations with research institutions drive innovation in hereditary angioedema therapies?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the hereditary angioedema market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the hereditary angioedema market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the hereditary angioedema industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The hereditary angioedema market was valued at USD 3.5 billion in 2023, driven by rising hereditary angioedema prevalence, advancements in genetic research, increased awareness and early diagnosis, a focus on prophylactic treatments, and regulatory support for rare disease therapies. It is expected to grow at a CAGR of 7.4% during the period 2024-2032 and likely to reach a market value of USD 6.7 billion by 2032.
Hereditary Angioedema Market Analysis
Hereditary angioedema is a rare genetic disorder characterised by sudden, recurrent episodes of severe swelling in various parts of the body, including the hands, feet, face, and airways. This condition is often triggered by stress or minor injuries and is caused by a deficiency or dysfunction in the C1 esterase inhibitor, leading to uncontrolled inflammation. Hereditary angioedema can be life-threatening when it affects the airways, making prompt diagnosis and treatment essential. Hereditary angioedema management focuses on preventing and controlling attacks through specialised therapies, such as C1 esterase inhibitors, bradykinin receptor antagonists, and kallikrein inhibitors, which provide relief and improve patients' quality of life.
Market Drivers
Rising Prevalence of Hereditary Angioedema: The increasing diagnosis of Hereditary angioedema is driving demand for targeted therapies. As awareness of hereditary angioedema grows among healthcare professionals and patients, more individuals are diagnosed, necessitating effective treatments to manage symptoms and prevent life-threatening complications.
Advancements in Genetic Research: Genetic research is improving understanding of hereditary angioedema, enabling the development of therapies that target the condition’s underlying causes. These advancements are driving pharmaceutical innovation, leading to the introduction of more specific and effective hereditary angioedema treatments, which is expanding the market.
Increased Awareness and Early Diagnosis: Awareness campaigns and improved diagnostic techniques are contributing to earlier hereditary angioedema diagnoses. Timely diagnosis allows for faster intervention, improving patient outcomes and increasing demand for therapies that help manage and prevent attacks, thus driving market growth.
Focus on Prophylactic Treatments: There is a growing focus on preventive treatments for hereditary angioedema, with patients and healthcare providers prioritising options that reduce attack frequency. This shift towards prophylactic therapies is driving demand for drugs that offer long-term management, such as C1 esterase inhibitors and kallikrein inhibitors.
Regulatory Support for Rare Disease Treatments: Regulatory bodies are increasingly supporting rare disease treatments by fast-tracking approvals and providing incentives for orphan drug development. This support encourages pharmaceutical companies to invest in hereditary angioedema treatment research and development, helping to expand the market and bring new therapies to patients more quickly.
Challenges
Limited Awareness in Developing Regions: In some developing countries, awareness of hereditary angioedema is low, resulting in underdiagnosis and insufficient treatment options. Limited healthcare infrastructure and a lack of knowledge among healthcare providers can hinder timely diagnosis, challenging efforts to expand access to hereditary angioedema treatments globally.
Adverse Effects of Current Therapies: Some hereditary angioedema treatments are associated with side effects, such as pain at the injection site, increased risk of infection, and allergic reactions. These adverse effects can reduce patient adherence, making it challenging for healthcare providers to balance treatment efficacy with patient comfort and safety.
Complex Treatment Regimens: Many hereditary angioedema therapies require regular administration via injection or infusion, which can be cumbersome for patients. This complexity can discourage adherence to long-term treatments, creating a challenge in ensuring consistent symptom control and attack prevention.
Challenges in Accurate Diagnosis: Accurate hereditary angioedema diagnosis can be challenging due to its rarity and symptom similarity to other conditions, such as allergies. Misdiagnosis can lead to inappropriate treatment, further complicating patient care and delaying access to effective hereditary angioedema therapies.
Future Opportunities
Expansion of Prophylactic Treatment Options: The market for prophylactic hereditary angioedema treatments is expanding as patients seek long-term management solutions. Pharmaceutical companies investing in developing and improving preventive therapies can capture a growing market segment focused on reducing attack frequency and improving quality of life.
Growing Demand for Personalised Medicine: Advances in genetic research offer opportunities to develop personalised hereditary angioedema treatments tailored to individual patient profiles. Personalised therapies that address specific genetic markers and treatment responses can enhance efficacy, providing patients with more targeted and effective care.
Emerging Markets with Improved Healthcare Access: Emerging markets, particularly in Asia and Latin America, present significant growth opportunities as healthcare access and infrastructure improve. Pharmaceutical companies can expand their reach by offering affordable and accessible hereditary angioedema treatments in these regions, broadening market potential.
Development of Oral Treatment Options: The development of oral hereditary angioedema treatments is an opportunity to provide more convenient options for patients. Oral medications eliminate the need for injections or infusions, improving patient adherence and potentially capturing a segment of the market seeking simplified treatment regimens.
Collaborations with Research Institutions: Collaborating with academic and research institutions can accelerate hereditary angioedema treatment development. Partnerships in research and clinical trials facilitate knowledge sharing and resource pooling, helping pharmaceutical companies bring new therapies to market more efficiently.
Hereditary Angioedema Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the market's future direction. These trends are expected to influence the landscape significantly, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
- Shift Towards Subcutaneous Administration
- Increasing Focus on Prophylactic Therapies
- Advancements in Biologic Therapies
- Rising Investment in Orphan Drugs
- Integration of Digital Health Tools
- Focus on Patient Education and Support
Hereditary Angioedema Market Segmentation
Market Breakup by Drug Class
- C1 Esterase Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
- Others
Market Breakup by Route of Administration
- Intravenous
- Subcutaneous
- Others
Market Breakup by End User
- Hospitals
- Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Hereditary Angioedema Market Competitive Landscape
Key players in the hereditary angioedema market include Takeda Pharmaceutical Company, CSL Behring, Pharvaris N.V., BioCryst Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Sanofi S.A., BioMarin Pharmaceutical Inc., Adverum Biotechnologies Inc., and Novartis AG. These companies focus on developing innovative hereditary angioedema treatments, investing in genetic research, and advancing biological therapies to provide effective management options. They are also pursuing strategic collaborations and clinical trials to enhance their offerings, aiming to address unmet patient needs and expand their presence in the rare disease treatment market.
Key Questions Answered in the Report
What are the primary drivers of growth in the hereditary angioedema market?
How are advancements in genetic research influencing new treatments for hereditary angioedema?
What challenges do patients and healthcare providers face with current hereditary angioedema therapies?
Which regions are expected to see the highest demand for hereditary angioedema treatments?
How is regulatory support affecting the development of rare disease therapies?
What role do prophylactic treatments play in managing hereditary angioedema?
How are digital health tools integrated into hereditary angioedema management for better patient outcomes?
What trends are emerging in the development of biologic therapies for hereditary angioedema?
Which drug classes are the most commonly used for hereditary angioedema, and why?
What strategies are leading companies using to expand their presence in emerging markets?
How is the demand for subcutaneous administration impacting the hereditary angioedema treatment landscape?
How do collaborations with research institutions drive innovation in hereditary angioedema therapies?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the hereditary angioedema market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the hereditary angioedema market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the hereditary angioedema industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Hereditary Angioedema Market Overview – 8 Major Markets
- 3.1 Hereditary Angioedema Market Historical Value (2018-2024)
- 3.2 Hereditary Angioedema Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Hereditary Angioedema Market Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Hereditary Angioedema Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 Germany
- 7.1.1.4 France
- 7.1.1.5 Italy
- 7.1.1.6 Spain
- 7.1.1.7 Japan
- 7.1.1.8 India
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 Germany
- 7.1.2.4 France
- 7.1.2.5 Italy
- 7.1.2.6 Spain
- 7.1.2.7 Japan
- 7.1.2.8 India
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 Germany
- 7.1.3.4 France
- 7.1.3.5 Italy
- 7.1.3.6 Spain
- 7.1.3.7 Japan
- 7.1.3.8 India
- 8 Hereditary Angioedema Market Landscape – 8 Major Markets
- 8.1 Hereditary Angioedema Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Hereditary Angioedema Market: Product Landscape
- 8.2.1 Analysis by Drug Class
- 8.2.2 Analysis by Route of Administration
- 9 Hereditary Angioedema Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Hereditary Angioedema Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Hereditary Angioedema Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Hereditary Angioedema Market (2018-2034) by Drug Class
- 12.1.1 Market Overview
- 12.1.2 C1 Esterase Inhibitor
- 12.1.3 Selective Bradykinin B2 Receptor Antagonist
- 12.1.4 Kallikrein Inhibitor
- 12.1.5 Others
- 12.2 Hereditary Angioedema Market (2018-2034) by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Intravenous
- 12.2.3 Subcutaneous
- 12.2.4 Others
- 12.3 Hereditary Angioedema Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Clinics
- 12.3.4 Others
- 12.4 Hereditary Angioedema Market (2018-2034) by Country
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 United Kingdom
- 12.4.4 Germany
- 12.4.5 France
- 12.4.6 Italy
- 12.4.7 Spain
- 12.4.8 Japan
- 12.4.9 India
- 13 United States Hereditary Angioedema Market (2018-2034)
- 13.1 United States Hereditary Angioedema Market Historical Value (2018-2024)
- 13.2 United States Hereditary Angioedema Market Forecast Value (2025-2034)
- 13.3 United States Hereditary Angioedema Market (2018-2034) by Drug Class
- 13.3.1 Market Overview
- 13.3.2 C1 Esterase Inhibitor
- 13.3.3 Selective Bradykinin B2 Receptor Antagonist
- 13.3.4 Kallikrein Inhibitor
- 13.3.5 Others
- 13.4 United States Hereditary Angioedema Market (2018-2034) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Intravenous
- 13.4.3 Subcutaneous
- 13.4.4 Others
- 13.5 United States Hereditary Angioedema Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Clinics
- 13.5.4 Others
- 14 United Kingdom Hereditary Angioedema Market (2018-2034)
- 14.1 United Kingdom Hereditary Angioedema Market Historical Value (2018-2024)
- 14.2 United Kingdom Hereditary Angioedema Market Forecast Value (2025-2034)
- 14.3 United Kingdom Hereditary Angioedema Market (2018-2034) by Drug Class
- 14.3.1 Market Overview
- 14.3.2 C1 Esterase Inhibitor
- 14.3.3 Selective Bradykinin B2 Receptor Antagonist
- 14.3.4 Kallikrein Inhibitor
- 14.3.5 Others
- 14.4 United Kingdom Hereditary Angioedema Market (2018-2034) by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Intravenous
- 14.4.3 Subcutaneous
- 14.4.4 Others
- 14.5 United Kingdom Hereditary Angioedema Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals
- 14.5.3 Clinics
- 14.5.4 Others
- 15 France Hereditary Angioedema Market (2018-2034)
- 15.1 France Hereditary Angioedema Market Historical Value (2018-2024)
- 15.2 France Hereditary Angioedema Market Forecast Value (2025-2034)
- 15.3 France Hereditary Angioedema Market (2018-2034) by Drug Class
- 15.3.1 Market Overview
- 15.3.2 C1 Esterase Inhibitor
- 15.3.3 Selective Bradykinin B2 Receptor Antagonist
- 15.3.4 Kallikrein Inhibitor
- 15.3.5 Others
- 15.4 France Hereditary Angioedema Market (2018-2034) by Route of Administration
- 15.4.1 Market Overview
- 15.4.2 Intravenous
- 15.4.3 Subcutaneous
- 15.4.4 Others
- 15.5 France Hereditary Angioedema Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospitals
- 15.5.3 Clinics
- 15.5.4 Others
- 16 Italy Hereditary Angioedema Market (2018-2034)
- 16.1 Italy Hereditary Angioedema Market Historical Value (2018-2024)
- 16.2 Italy Hereditary Angioedema Market Forecast Value (2025-2034)
- 16.3 Italy Hereditary Angioedema Market (2018-2034) by Drug Class
- 16.3.1 Market Overview
- 16.3.2 C1 Esterase Inhibitor
- 16.3.3 Selective Bradykinin B2 Receptor Antagonist
- 16.3.4 Kallikrein Inhibitor
- 16.3.5 Others
- 16.4 Italy Hereditary Angioedema Market (2018-2034) by Route of Administration
- 16.4.1 Market Overview
- 16.4.2 Intravenous
- 16.4.3 Subcutaneous
- 16.4.4 Others
- 16.5 Italy Hereditary Angioedema Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospitals
- 16.5.3 Clinics
- 16.5.4 Others
- 17 Spain Hereditary Angioedema Market (2018-2034)
- 17.1 Spain Hereditary Angioedema Market Historical Value (2018-2024)
- 17.2 Spain Hereditary Angioedema Market Forecast Value (2025-2034)
- 17.3 Spain Hereditary Angioedema Market (2018-2034) by Drug Class
- 17.3.1 Market Overview
- 17.3.2 C1 Esterase Inhibitor
- 17.3.3 Selective Bradykinin B2 Receptor Antagonist
- 17.3.4 Kallikrein Inhibitor
- 17.3.5 Others
- 17.4 Spain Hereditary Angioedema Market (2018-2034) by Route of Administration
- 17.4.1 Market Overview
- 17.4.2 Intravenous
- 17.4.3 Subcutaneous
- 17.4.4 Others
- 17.5 Spain Hereditary Angioedema Market (2018-2034) by End User
- 17.5.1 Market Overview
- 17.5.2 Hospitals
- 17.5.3 Clinics
- 17.5.4 Others
- 18 Japan Hereditary Angioedema Market
- 18.1 Japan Hereditary Angioedema Market Historical Value (2018-2024)
- 18.2 Japan Hereditary Angioedema Market Forecast Value (2025-2034)
- 18.3 Japan Hereditary Angioedema Market (2018-2034) by Drug Class
- 18.3.1 Market Overview
- 18.3.2 C1 Esterase Inhibitor
- 18.3.3 Selective Bradykinin B2 Receptor Antagonist
- 18.3.4 Kallikrein Inhibitor
- 18.3.5 Others
- 18.4 Japan Hereditary Angioedema Market (2018-2034) by Route of Administration
- 18.4.1 Market Overview
- 18.4.2 Intravenous
- 18.4.3 Subcutaneous
- 18.4.4 Others
- 18.5 Japan Hereditary Angioedema Market (2018-2034) by End User
- 18.5.1 Market Overview
- 18.5.2 Hospitals
- 18.5.3 Clinics
- 18.5.4 Others
- 19 India Hereditary Angioedema Market
- 19.1 India Hereditary Angioedema Market (2018-2034) Historical Value (2018-2024)
- 19.2 India Hereditary Angioedema Market (2018-2034) Forecast Value (2025-2034)
- 19.3 India Hereditary Angioedema Market (2018-2034) by Drug Class
- 19.3.1 Market Overview
- 19.3.2 C1 Esterase Inhibitor
- 19.3.3 Selective Bradykinin B2 Receptor Antagonist
- 19.3.4 Kallikrein Inhibitor
- 19.3.5 Others
- 19.4 India Hereditary Angioedema Market (2018-2034) by Route of Administration
- 19.4.1 Market Overview
- 19.4.2 Intravenous
- 19.4.3 Subcutaneous
- 19.4.4 Others
- 19.5 India Hereditary Angioedema Market (2018-2034) by End User
- 19.5.1 Market Overview
- 19.5.2 Hospitals
- 19.5.3 Clinics
- 19.5.4 Others
- 20 Regulatory Framework
- 20.1 Regulatory Overview
- 20.2 US FDA
- 20.3 EU EMA
- 20.4 Japan PMDA
- 20.5 India CDSCO
- 20.6 Others
- 21 Patent Analysis
- 21.1 Analysis by Drug Class of Patent
- 21.2 Analysis by Publication Year
- 21.3 Analysis by Issuing Authority
- 21.4 Analysis by Patent Age
- 21.5 Analysis by CPC Analysis
- 21.6 Analysis by Patent Valuation
- 21.7 Analysis by Key Players
- 22 Clinical Trials and Pipeline Analysis
- 22.1 Analysis by Trial Registration Year
- 22.2 Analysis by Trial Status
- 22.3 Analysis by Trial Phase
- 22.4 Analysis by Therapeutic Area
- 22.5 Analysis by Geography
- 22.6 Drug Class Pipeline Assessment
- 23 Grants Analysis
- 23.1 Analysis by Year
- 23.2 Analysis by Amount Awarded
- 23.3 Analysis by Issuing Authority
- 23.4 Analysis by Grant Application
- 23.5 Analysis by Funding Institute
- 23.6 Analysis by NIH Departments
- 23.7 Analysis by Recipient Organization
- 24 Funding and Investment Analysis
- 24.1 Analysis by Funding Instances
- 24.2 Analysis by Drug Class of Funding
- 24.3 Analysis by Funding Amount
- 24.4 Analysis by Leading Players
- 24.5 Analysis by Leading Investors
- 24.6 Analysis by Geography
- 25 Strategic Initiatives
- 25.1 Analysis by Partnership Instances
- 25.2 Analysis by Drug Class of Partnership
- 25.3 Analysis by Leading Players
- 25.4 Analysis by Geography
- 26 Supplier Landscape
- 26.1 Market Share by Top 5 Companies
- 26.2 Takeda Pharmaceutical Company
- 26.2.1 Financial Analysis
- 26.2.2 Product Portfolio
- 26.2.3 Demographic Reach and Achievements
- 26.2.4 Company News and Developments
- 26.2.5 Certifications
- 26.3 CSL Behring
- 26.3.1 Financial Analysis
- 26.3.2 Product Portfolio
- 26.3.3 Demographic Reach and Achievements
- 26.3.4 Company News and Developments
- 26.3.5 Certifications
- 26.4 Pharvaris N.V.
- 26.4.1 Financial Analysis
- 26.4.2 Product Portfolio
- 26.4.3 Demographic Reach and Achievements
- 26.4.4 Company News and Developments
- 26.4.5 Certifications
- 26.5 BioCryst Pharmaceutical Inc.
- 26.5.1 Financial Analysis
- 26.5.2 Product Portfolio
- 26.5.3 Demographic Reach and Achievements
- 26.5.4 Company News and Developments
- 26.5.5 Certifications
- 26.6 Ionis Pharmaceuticals Inc.
- 26.6.1 Financial Analysis
- 26.6.2 Product Portfolio
- 26.6.3 Demographic Reach and Achievements
- 26.6.4 Company News and Developments
- 26.6.5 Certifications
- 26.7 KalVista Pharmaceuticals Inc.
- 26.7.1 Financial Analysis
- 26.7.2 Product Portfolio
- 26.7.3 Demographic Reach and Achievements
- 26.7.4 Company News and Developments
- 26.7.5 Certifications
- 26.8 Sanofi S.A.
- 26.8.1 Financial Analysis
- 26.8.2 Product Portfolio
- 26.8.3 Demographic Reach and Achievements
- 26.8.4 Company News and Developments
- 26.8.5 Certifications
- 26.9 BioMarin Pharmaceutical Inc.
- 26.9.1 Financial Analysis
- 26.9.2 Product Portfolio
- 26.9.3 Demographic Reach and Achievements
- 26.9.4 Company News and Developments
- 26.9.5 Certifications
- 26.10 Adverum Biotechnologies Inc.
- 26.10.1 Financial Analysis
- 26.10.2 Product Portfolio
- 26.10.3 Demographic Reach and Achievements
- 26.10.4 Company News and Developments
- 26.10.5 Certifications
- 26.11 Novartis AG
- 26.11.1 Financial Analysis
- 26.11.2 Product Portfolio
- 26.11.3 Demographic Reach and Achievements
- 26.11.4 Company News and Developments
- 26.11.5 Certifications
- 27 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.